XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one operating segment focused on developing and commercializing innovative therapeutics primarily in the U.S. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.
The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the chief executive officer, who is the Company's chief operating decision maker, or CODM, in assessing segment performance and deciding how to allocate resources on a consolidated basis.
The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using income from operations. Net income is also a measure that is considered in monitoring budget versus actual results. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table presents information about reported segment revenues, segment profit and significant segment expenses for the three months ended March 31, 2025 and 2024:
 Three Months Ended March 31,
 20252024
Revenues$57,336 $32,607 
Less:
Direct cost of product and other revenue5,059 741 
Panion royalty2,566 1,853 
Amortization of intangible asset— 9,011 
Research and development9,754 9,731 
Selling, general and administrative25,742 25,438 
License701 711 
Restructuring— 58 
Income (loss) from operations13,514 (14,936)
Other income (expense)
Interest expense(7,770)(2,498)
Other (expense) income213 95 
Change in fair value of warrant liability155 (129)
Loss on extinguishment of debt— (517)
Net income (loss) before income taxes$6,112 $(17,985)
Net income (loss)$6,112 $(17,985)